Medicare Part D coverage · lanthanum carbonate · RxCUI 1551886

lanthanum carbonate 750 MG Oral Powder [Fosrenol]

Per the CMS 2026 Part D formulary file, lanthanum carbonate 750 MG Oral Powder [Fosrenol] is covered by 1 Medicare Part D plans (0% of enrollable products), averaging Tier 5, with prior authorization required on 100% of covering formularies.

0%
Plan coverage
1
Plans covering
T5
Avg tier
100%
Prior auth required

Verify with CMS →

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.

What the CMS Formulary Data Shows for lanthanum carbonate 750 MG Oral Powder [Fosrenol]

Per the CMS 2026 Part D formulary file, lanthanum carbonate 750 MG Oral Powder [Fosrenol] (RxNorm concept RXCUI 1551886, generic name lanthanum carbonate) appears on 1 distinct formulary file spanning 1 Medicare Part D plan offering - 0% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 5 to Tier 5, with a cross-plan average of Tier 5.

Real-world access to lanthanum carbonate 750 MG Oral Powder [Fosrenol] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 13,966 Part D beneficiaries filled lanthanum carbonate 750 MG Oral Powder [Fosrenol] in 2023, with total plan-and-beneficiary spending of $58,352,402 and an average per-beneficiary annual cost of $4,178.18. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry lanthanum carbonate 750 MG Oral Powder [Fosrenol] today.

Coverage Details

Formularies covering
1
Plans covering
1
Coverage rate
0%
Tier range
Tier 5, Specialty
Average tier
Tier 5, Specialty

Restrictions

Prior authorization required
100% of formularies
Step therapy required
0% of formularies
Quantity limits
0% of formularies

2023 Medicare Spending

Beneficiaries
13,966
Total spending
$58,352,402
Avg per beneficiary
$4,178.18

Tier Distribution Across Plans

1 plans
Tier 5, Specialty

Medicare Advantage Plans (MA-PD) Covering lanthanum carbonate 750 MG Oral Powder [Fosrenol]

1 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
CareOregon Advantage Plus (HMO D-SNP) Health Plan OF Careoregon, Inc. T5 Yes $0 OR

Frequently Asked Questions

Is lanthanum carbonate 750 MG Oral Powder [Fosrenol] covered by Medicare Part D?

Yes, lanthanum carbonate 750 MG Oral Powder [Fosrenol] is covered by 1 Medicare Part D plans (0% of all Part D formularies).

What tier is lanthanum carbonate 750 MG Oral Powder [Fosrenol] on Medicare Part D plans?

lanthanum carbonate 750 MG Oral Powder [Fosrenol] averages Tier 5 across Part D plans, ranging from Tier 5 to Tier 5.

Does lanthanum carbonate 750 MG Oral Powder [Fosrenol] require prior authorization?

100% of Part D formularies require prior authorization for lanthanum carbonate 750 MG Oral Powder [Fosrenol]. Step therapy: 0%. Quantity limits: 0%.

How much does Medicare spend on lanthanum carbonate 750 MG Oral Powder [Fosrenol]?

In 2023, total Medicare Part D spending on lanthanum carbonate 750 MG Oral Powder [Fosrenol] was $58,352,402, covering 13,966 beneficiaries. The average spend per beneficiary was $4,178.18.

Read our methodology - how this data is sourced, computed, and verified.

Nationwide similar Part D drugs

Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.

Closest average formulary tier

Similar prior-authorization rate

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare